Dr. Kyunghee Burkitt, DO

Dr. Burkitt practices at Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation.

Dr. Burkitt's NPI, 1346652245, was assigned on May 27, 2014. Dr. Burkitt graduated from Michigan State University College of Osteopathic Medicine in 2014. Dr. Burkitt holds Ohio license 34.014633.

Dr. Burkitt's primary practice is Cleveland Clinic Main Campus, at 9500 Euclid Avenue, Cleveland, OH 44195 in Cuyahoga County. The practice phone is (216) 952-9829.

Dr. Burkitt's primary practice is Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation. Dr. Burkitt is also affiliated with Cleveland Clinic Akron General. The medical group on file is Cleveland Clinic. Dmand AI also links Dr. Burkitt to 1 more hospital, 2 clinical labs and 1 medical group, each named with a free account. Dr. Burkitt's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Burkitt practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Burkitt's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Burkitt is licensed in Ohio.

CMS data shows 206 Medicare services from Dr. Burkitt across 4 procedure codes in 2024, for 74 Medicare patients. Medicare paid $18,480 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 74 Medicare patients who saw Dr. Burkitt in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have high blood pressure, and 70% have high cholesterol. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Burkitt's median patient age at 66, with 31% women.

In 2024, Dr. Burkitt wrote 301 Medicare Part D claims for 55 patients. 69% of them were for generic drugs. CMS names the drug for 207 of them, across 11 drugs with 11 or more claims each, at $1,182,608 in total drug cost. In 2023, CMS named 98 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Burkitt for performance year 2024, reported through an alternative payment model (APM). Dr. Burkitt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Burkitt as offering telehealth.

Dmand AI links 10 papers to Dr. Burkitt, published from 2018 to 2025. 2021 was the busiest year, with 3. The most frequent topics are Head and Neck Neoplasms, Histone-Lysine N-Methyltransferase and Squamous Cell Carcinoma of Head and Neck. Dr. Burkitt has published most often in Oral Oncol. Dr. Burkitt's most frequent co-authors are Benjamin Jonah Bernard, MD, Theodore Vougiouklakis, MD and Nicole Mccormick Fowler, MD.

Dmand AI links Dr. Burkitt to 1 clinical trial. Conditions studied include Oropharyngeal Neoplasms and Pharyngeal Neoplasms.

CMS Open Payments shows 1 general payment to Dr. Burkitt from 1 drug or device company in 2023. Food and beverage make up the largest share, 100% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $20. It also lists 1 research payment totaling $620 in 2025.

Dr. Burkitt graduated from Michigan State University College of Osteopathic Medicine in 2014.